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Currently, there is no effective treatment for metastatic uveal melanoma (UVM). Here, we aimed 
to identify the mechanism involving intrinsic chemoresistance of metastatic UVM and the relevant 
therapeutic targets for UVM. We analyzed cohorts of 80 and 67 patients with primary UVM and skin 
cutaneous melanoma (SKCM), respectively, using The Cancer Genome Atlas dataset. Mutational 
burdens identified by whole exome sequencing were significantly lower in UVM than in SKCM patients. 
COSMIC mutational signature analysis identified that most of the mutations in UVM patients (>90%) 
were associated with spontaneous deamination of 5-methylcytosine or defective mismatch repair. 
Transcriptome analysis revealed that the MYC signature was more enriched in UVM patients, as 
compared to SKCM patients. Fifty-nine (73.8%) of 80 UVM patients showed gains in MYC copy number, 
and a high MYC copy number was associated with aggressive clinicopathological features of tumors and 
poor survival. Kinome-wide siRNA library screening identified several therapeutic targets, reported as 
synthetic lethal targets for MYC-addicted cancers. Notably, UVM cell lines showed high susceptibility 
to a WEE1 inhibitor (MK-1775; adavosertib) at a clinically tolerable dose. Overall, our study identified 
high MYC activity in UVM, and suggested G2/M checkpoint inhibitors as effective therapeutic targets 
for UVM.
Uveal melanoma (UVM) and skin cutaneous melanoma (SKCM) are both derived from melanocytes but show 
different characteristics, including significant differences in tumorigenesis, genetic alterations, and therapeutic 
responses1. The BRAF V600E mutation commonly seen in SKCM patients is not frequently observed in UVM 
patients, and GNAQ/GNA11, SF3B1, EIF1AX, and BAP1 mutations seen in UVM patients are rarely observed in 
SKCM patients2,3. Vemurafenib, a targeted agent for BRAF V600E, significantly improves therapeutic outcomes 
in SKCM patients4. The GNAQ/GNA11 mutations frequently observed in UVM patients have also been reported 
to activate the MAPK pathway, but clinical trials with the MEK1/2 inhibitor, selumetinib, have failed to improve 
survival5–7.
The difference in therapeutic outcomes between the two tumors has been further verified by the recent intro-
duction of immune checkpoint inhibitors. Immunotherapy has led to favorable therapeutic outcomes for SKCM 
patients8. Some studies have reported the response to immune checkpoint inhibitors in UVM, but the effect 
was limited to minority of UVM9–12. Despite excellent local control, blood-borne distant metastasis occurs in 
up to 50% of UVM patients and approximately 85% of patients with metastasis die within 1 year13. Currently, 
there is no effective treatment for metastatic UVM, and the mechanism involving chemoresistance to most 
treatments remains poorly understood. In this study, we analyzed the whole exome sequencing and transcrip-
tome (mRNA) sequencing data of UVMs and SKCMs in The Cancer Genome Atlas (TCGA) dataset, and per-
formed kinome-wide siRNA library screening to characterize UVM and to identify potential therapeutic targets 
of UVM.
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Results
Study population. Eighty and 67 patients with primary UVMs and SKCMs, respectively, in TCGA datasets 
were identified and included in this study. The mean ages of the patients were 62.2 ± 14.0 and 62.8 ± 14.5 years 
in the UVM and SKCM groups, respectively (P = 0.790). Of the UVM and SKCM patients, 45 (56.3%) and 42 
(62.7%) were male, respectively (P = 0.501). There were no significant differences in age and sex between the 
UVM and SKCM groups.
Mutational burden and signatures. Mutational burdens identified by whole exome sequencing were sig-
nificantly higher in SKCM than in UVM patients (P < 0.001). The median numbers of mutations were 19 and 321 
in the UVM and SKCM patients, respectively. No double nucleotide variant (DNV) was observed in any patients 
with UVM. The details of mutational burden are presented in Supplementary Table 1.
A total of 1,994 and 32,508 single nucleotide variants (SNVs) and DNVs were identified in 80 UVM and 67 
SKCM patients, respectively, and were included in the COSMIC mutational signature analyses. The most com-
mon mutational signature identified in UVM was signature 1 (69.8%), which was the result of endogenous muta-
tional processes initiated by spontaneous deamination of 5-methylcytosine (Fig. 1a and Supplementary Fig. 1). 
Signature 6 (22.7%) and signature 15 (3.7%), which were associated with defective DNA mismatch repair, were 
also identified in UVM patients. No mutational signature related to ultraviolet light (UV) exposure was found 
in UVM patients. Regarding SKCM patients, 77.8% were designated as signature 7, which was associated with 
UV light exposure. Signatures 1, 23, 4, and 10 were also identified in SKCM patients (Fig. 1b and Supplementary 
Fig. 2). These signatures were likely to be due to tobacco-induced mutations (signature 4) and error-prone poly-
merase POLE (signature 10). In uveal melanoma, there was no transcriptional strand bias in the somatic muta-
tions (SNVs and DNVs). The somatic mutations were frequently observed in the chromatin regions showing high 
DNase I hypersensitivity (51.6%, indicating regulatory elements) or high GC contents (59.4%).
Figure 1. Comparison of exome and transcriptome sequencing data between uveal melanomas and skin 
cutaneous melanomas. (a) Mutational signature analysis for primary uveal melanomas. (b) Mutational signature 
for primary skin cutaneous melanomas. (c,d) Gene Set Enrichment Analysis plots show upregulation of MYC 
signature genes in primary uveal melanomas when compared with skin cutaneous melanomas. The genes in the 
genesets are generated from primary epithelial breast cancer cell cultures over-expressing the MYC gene.
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MYC upregulation in UVM patients. Using the transcriptome sequencing data, we performed a gene set 
enrichment analysis (GSEA) using MSigDB C6 oncogenic signatures to identify the difference in gene expres-
sion patterns between UVM and SKCM patients. Most oncogenic signatures including YAP, EGFR, KRAS, 
BRAF, and MTOR were enriched in SKCM patients (Supplementary Table 2). MYC signature genes were signif-
icantly enriched in UVM patients (normalized enrichment score = 1.46, normalized p < 0.001, FDR q = 0.084) 
(Fig. 1c,d). The expression levels of MYC (c-myc) and MYCL1 (l-myc) were higher in UVM patients than in 
SKCM patients (P < 0.001 and P = 0.001, respectively). There was no statistically significant difference in the 
MYCN (n-myc) expression level (Fig. 2a–c). When the expression levels of the MYC network genes were com-
pared, MAX, MNT, MXD4, MXI1, and MYC expression levels were increased in UVM patients (Fig. 2d).
MYC copy number variation in UVM patients. MYC copy number was increased in 59 (73.8%) out of 
80 UVM patients. The MYC copy number gain was associated with UVM-specific survival (P = 0.028; Fig. 3a). 
A worse UM-specific survival was observed in patients with a larger MYC copy number (P = 0.028 for trend; 
Fig. 3b). A high MYC copy number was associated with marked pigmentation (P < 0.001), high mitotic count 
(P = 0.021), and a large tumor basal diameter (P = 0.040). The clinicopathological features of patients with or 
without gain of the MYC copy number are presented in Table 1. Notably, significantly more BAP1 mutations were 
Figure 2. Comparison of the expression levels of MYC and its related genes. (a–c) Comparison of MC, 
MYCN, and MYCL expressions between uveal melanoma and skin cutaneous melanoma. (d) A heat map of the 
expression levels of MYC-related genes in primary uveal melanomas and skin cutaneous melanomas.
Figure 3. Kaplan-Meier curves showing the association between uveal melanoma-specific survival and MYC 
copy number. (a) Comparison between tumors with normal copy number (N = 2) and tumors with high copy 
number (N > 2). (b) Trends showing the survival curves of tumors with various copy numbers.
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observed in patients with high MYC copy number (P < 0.002). In multivariate cox proportional hazards model, 
hazard ratios were 2.27 (P = 0.201) and 5.45 (P = 0.001) for MYC copy number gain and BAP1 mutation, respec-
tively. Harrell’s C indices were 0.623 and 0.687 for for MYC copy number gain and BAP1 mutation, respectively.
Kinome-wide siRNA library screening to identify synthetic lethal targets for UVM. Using the 
92.1 UVM cell line, we screened a siRNA library of 715 genes across the human kinome to identify synthetic lethal 
targets for UVM (Fig. 4a and Supplementary Table 3). Pearson’s correlation coefficient between two biological 
replicates was 0.7425 (P < 0.001), indicating little variation. The screen identified five hits (WEE1, PLK1, CHEK1, 
PDPK1, and CDK11A) that significantly affected survival of 92.1 cells (Z-score < −2.5 in both replicates).
WEE1 as a therapeutic target for UVM. We added the selective WEE1 inhibitor (MK-1775) at con-
centrations of 250 or 500 nM to cell lines of multiple human cancers, including UVM (92.1 and OCM1), SKCM 
(SKMEL28), non-small cell lung cancer (A549), breast cancer (MCF7), mesothelioma (MSTO-211H and H2373), 
and pancreatic cancer (PANC1 and Mia-PaCa2). Treatment with the WEE1 inhibitor significantly reduced the 
cell viability of 92.1 and OCM1 UVM cells, compared with other cancer cells (Fig. 4b).
Discussion
During tumorigenesis, somatic genome mutations occur. SNVs, small insertions/deletions, and copy number var-
iations of the genome alter the function of oncogenes and tumor suppressor genes, and can cause cancer14. Intense 
research efforts regarding cancer genomes have identified several oncogenic pathways important in human can-
cers, and have led to improved therapeutic outcomes for tumors with EGFR, ALK, and BRAF mutations15. Cancer 
genome sequencing studies using UVM have identified frequent mutations in GNAQ/GNA112. Mutant GNAQ/
GNA11-induced activation of the MAPK and Hippo-YAP pathways has been reported in many basic and transla-
tional studies, and has suggested as essential for tumorigenesis of UVM7,16. However, these studies have not led to 
an improvement in clinical outcomes of UVM patients. Clinical trials using the MEK1/2 inhibitor, selumetinib, 
have failed to increase the overall survival of metastatic UVM patients, and drugs targeting the Hippo-YAP path-
way are not currently available5,6. In addition, metastatic UVM patients have shown intrinsic resistance to various 
anti-cancer agents including immune checkpoint inhibitors9. Thus, an effective treatment of metastatic UVM 




(CN > 2) P-value
Number of Patients 21 59 —
Age, Median (IQR) 60.5 (51.1–72.5) 65.2 (53.3–76.4) 0.240
Male, No. (%) 10 (47.6%) 35 (59.3%) 0.444
AJCC stage 0.511
   Stage IIA, No. (%) 2 (9.5%) 2 (3.4%)
   Stage IIB, No. (%) 10 (47.6%) 22 (37.3%)
   Stage IIIA, No. (%) 7 (33.3%) 20 (33.9%)
   Stage IIIB, No. (%) 2 (9.5 %) 8 (13.6%)
   Stage IIIC, No. (%) 0 (0%) 3 (5.1%)
   Stave IV, No. (%) 0 (0%) 4 (6.8%)
Dominant cell types
   Spindle, No. (%) 18 (85.7%) 39 (66.1%) 0.101
   Epithelioid, No. (%) 3 (14.3%) 20 (33.9%)
Pigmentation
   Minimal, No. (%) 18 (85.7%) 21 (35.6%) <0.001
   Marked, No. (%) 3 (14.3%) 38 (64.4%)
Mitotic count
   0–5/HPF, No. (%) 21 (100%) 42 (71.2%) 0.021
   5–10/HPF, No. (%) 0 (0%) 11 (18.6%)
   >11/HPF, No. (%) 0 (0%) 6 (10.2%)
Basal diameter(clinical), Median (IQR), mm 15.9 (13.2–17.0) 17.0 (15.1–18.0) 0.040
Basal diameter (pathological), Median (IQR), mm 15.5 (12.0–18.0) 17.0 (15.0–20.0) 0.094
Tumor thickness, Median (IQR), mm 10.0 (8.4–12.0) 11.0 (8.7–12.2) 0.390
GNAQ/11 mutation, No. (%) 19 (90.5%) 55 (93.2%) 0.650
BAP1 mutation, No. (%) 3 (14.3%) 32 (54.2%) 0.002
EIF1AX mutation, No. (%) 10 (47.6%) 0 (0%) <0.001
SF3B1 mutation, No. (%) 3 (14.3%) 15 (25.4%) 0.373
Table 1. Clinicopathological features of patients with or without gain of MYC copy number. CN = copy 
number, IQR = interquartile range, No. = Number AJCC = American Joint Committee on Cancer.
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In the present study, we conducted multi-platform omics analyses to identify molecular characteristics and 
therapeutic targets for UVM. Analysis of whole exome sequencing data revealed that somatic mutations in UVM 
patients were associated with spontaneous deamination or impaired DNA mismatch repair, but were not asso-
ciated with UV light. We also identified that most UVMs underwent malignant transformation involving less 
somatic mutations when compared with SKCMs. Analysis of transcriptome sequencing data suggested a possible 
reason for this difference. Most oncogenic signatures were high in SKCM patients, whereas the MYC signature 
was significantly higher in UVM patients, which was possibly the result of a MYC copy number gain. Even when 
comparing primary/metastatic SKCM and UVM transcriptomes in the TCGA dataset, the Gene Set Enrichment 
Analysis (GSEA) of the MYC signature is valid (normalized p-value = 0.006, FDR q-value = 0.146). We believe 
that the GSEA of the MYC signature comprehensively evaluated changes in many genes affected by MYC, thus 
better reflecting the activity of MYC in the tumor than the MYC mRNA level or copy number.
MYC and its paralogs, MYCN and MYCL, are well-known oncogenes and frequently amplified in many the 
human cancers17. Following diverse mitogenic and developmental signals, the upregulated and deregulated MYC 
proteins cause broad changes in gene expressions, resulting in increased cell proliferation17. In MYC-driven can-
cers, MYC deregulation affects gene expression, DNA replication, or repair processes, leading to oncogenic prolif-
eration18,19. In the present study, analyses of whole exome sequencing and transcriptome sequencing data revealed 
high MYC activity in UVM.
Emerging data have shown that MYC activation confers chemoresistance to cancer cells treated with BRAF, 
MEK, KRAS, or BET inhibitors20. Our results showed that the global chemoresistance found in metastatic UVM 
patients was possibly due to MYC deregulation resulting from a gain in copy number. Importantly, MYC copy 
number gain was associated with aggressive pathological features and poor survival outcomes in UVM patients. 
Because MYC deregulation is observed in multiple human cancers and associated with poor prognoses, there 
have been intense research efforts to develop treatments that target MYC21. However, direct inhibition of MYC is 
challenging due to the lack of a specific active site, so several methods have been tried to regulate MYC indirectly 
at the level of transcription (BRD4, CDK7, CDK9), translation (mTOR, CPEB), or protein stability (AURKA, 
PLK1)21. Our kinome-wide siRNA library screen also identified BRD4, AURKA, and PLK1 as therapeutic targets 
in 92.1 UVM cells.
Remarkably, the kinome-wide siRNA library screen identified the G2/M checkpoint proteins, WEE1 and 
CHEK1, as the strongest therapeutic targets for UVM. They have also been reported to be lethal targets for 
MYC-driven medulloblastoma, diffuse large B cell lymphoma, breast cancer, and lung cancer21–23. A mechanism 
involving the synthetic lethal effect of WEE1 inhibition on MYC-driven cancers includes the possibility that 
WEE1 enhances survival of cancer cells by protecting the cells from MYC-induced replicative stress, and by pro-
moting DNA damage repair24. In the present study, a cell viability test using multiple cancer cell lines showed that 
92.1 and OCM1 UVM cells were very susceptible to a WEE1 inhibitor (MK-1775) at a clinically tolerable dose.
In multivariate cox proportional hazard model, the hazard ratio was 2.271 for MYC copy number gain. 
Although the statistical significance of the MYC copy number gain did not come from the multivariate analy-
sis, it cannot be concluded at this time because of small number of tumor-specific death in the TCGA dataset. 
Considering the Harrell’s C indices for MYC copy number gain and BAP1 mutation, we think that both factors 
affect survival outcomes of uveal melanoma patients independently. A recent study has shown that 8q gains occur 
Figure 4. WEE1 as a therapeutic target for uveal melanoma. (a) The results of kinome-wide siRNA screening 
to identify therapeutic targets for uveal melanoma. (b) The cell viability of multiple cancer cells treated with the 
WEE1 inhibitor (MK-1775) at the indicated doses.
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early and subsequently increase during progression in metastatic UVMs using targeted sequencing technology25. 
Interestingly, some cases showed BAP1 mutation in primary tumors, but not in metastases, while high 8q copy 
number was detected in these metastases. Considering that MYC is located at the 8q24 locus, it is possible that the 
MYC copy number gain is associated with 8q gains in metastatic UVM. These findings may suggest that 8q gain 
and MYC copy number gain have distinct roles in metastasis apart from BAP1 mutations.
This study used exome and transcriptome data to elucidate the mechanism by which metastatic UVMs 
acquired chemoresistance. Combined with a kinome-wide siRNA library screen, our results identified UVM as a 
MYC-driven cancer, with several therapeutic targets. The G2/M checkpoint inhibitors are currently in clinical tri-
als for treatment of various MYC-driven cancers, including lung cancer (NCT02688907), lymphoma, and ovarian 
cancer23,26. Based on the present study, we expect that WEE1 inhibition will ameliorate intrinsic chemoresistance 
and increase the survival of metastatic UVM patients.
Methods
Study population and acquisition of TCGA data. The study population included primary UVM and 
SKCM patients in the TCGA dataset. Whole exome sequencing data and transcriptome sequencing data were 
obtained from Firebrowse (Broad Institute). The most recent follow-up survival data and clinicopathological 
information, including age, sex, tumor stage, pigmentation, mitotic count, tumor basal diameter, and thickness 
were downloaded using the R package TCGAbiolinks (last update: 2018-09-06; http://bioconductor.org/pack-
ages/release/bioc/html/TCGAbiolinks.html). All samples in TCGA have been collected and utilized follow-
ing strict human subject protection guidelines, informed consent, and institutional review board review of the 
protocols.
Mutation identification and mutational signature analysis. Whole exome sequencing data 
(Mutation Packager Oncotated Calls; downloaded from https://gdac.broadinstitute.org) were used for identifica-
tion of SNVs, DNVs, insertions, and deletions. SNV and DNV indicate a somatic variation in a single nucleotide 
or consecutive two nucleotides in tumor cells. For the analysis of somatic DNA mutations with DNA sequence 
contexts, we used a public web service program called MUTALISK (http://mutalisk.org)27. Mutational processes 
in tumors were estimated according to the COSMIC mutational signature28. The characteristics of the genome 
regions corresponding to somatic mutations (SNV and DNV) were also analyzed using MUTALISK. For DNase 
I hypersensitivity analysis, the 1-megabase interval chromosome region was categorized into a low (≤25th per-
centile), intermediate (25th–75th percentiles), or high (≥75th percentile) level based on the normalized read 
intensity. For GC content analysis, the ratios of the guanine (G) and cytosine (C) nucleotides were calculated in 
each 1 kilobase window. Subsequently, each bin was labeled as a low (≤25th percentile), intermediate (25th–75th 
percentile), or high (≥75th percentile) level. The detailed methods for each analysis were published elsewhere27.
Transcriptome analysis and MYC copy number variations. The mRNA expression (RNA Seq V2, 
RSEM) data were obtained from TCGA datasets for primary UVM and SKCM patients. Gene Set Enrichment 
Analysis (GSEA) was performed using the C6 MSigDB gene set database to identify gene sets enriched in primary 
UVMs29. The gene sets for the MYC signature used in this study included the 200 genes that were significantly 
upregulated (MYC_UP.V1_UP) or downregulated (MYC_UP.V1_DN) in primary epithelial breast cancer cell 
cultures overexpressing the c-MYC gene. Heatmaps were generated using Morpheus (Broad institute; https://
software.broadinstitute.org/morpheus/). The MYC copy number of each UVM patient was derived from previous 
studies using the FACET algorithms for calculations2.
Kinome-wide siRNA library screening. A kinome-wide siRNA library targeting 715 human kinases 
(Dharmacon, Lafayette, CO, USA) was used. Four different siRNAs targeting each kinase gene were spotted as 
a pool on 384-well plates (CELLSTAR; Greiner Bio-One, Monroe, NC, USA) using a Biomek FX Laboratory 
Automation Workstation (Beckman Coulter, Brea, CA, USA). Lipofectamine RNAiMAX (Invitrogen, Carlsbad, 
CA, USA) dissolved in Opti-MEM (Gibco, Gaithersburg, MD, USA) was added to the assay plates to perform 
reverse transfection. The final total siRNA concentration was 15 nM (3.75 nM for each siRNA targeting each 
kinase gene). The 92.1 cells were suspended and seeded onto the assay plates using a MultiFlo Microplate 
Dispenser (BioTek, Winnoski, VT, USA) at 850 cells/well with a final culture volume of 50 μL. The cells were 
incubated for 120 h, and then Cell Counting Kit-8 reagent (CCK8; Dojindo Molecular Technologies, Rockville, 
MD, USA) was added for 2 h to measure the cell viability. Viable cells were quantitated by measurement of the 
absorbance at 450 nm. Genes with Z-scores < −2.5 were considered therapeutic targets.
Cell viability assay. MK-1775 (Adavosertib; Selleckchem, Houston TX, USA) was used to evaluate the effect 
of the WEE1 inhibition on the viability of cancer cells. Multiple cancer cells were incubated for 24 h after plating, 
and then treated with WEE1 inhibitor for 72 h. Viable cells were quantitated using the CCK8 reagent.
Statistical analysis. The clinicopathological characteristics were compared using the chi-square or Fisher’s 
exact test for categorical variables. Student’s t-tests and the Mann-Whitney U test were used to compare two 
groups for continuous variables with and without normal distribution, respectively. The Kaplan-Meier method 
and the log-rank test were used for tumor-specific survival analyses. Cox proportional hazard model and Harrell’s 
C index were also used for survival analysis. A value of P < 0.05 was considered to indicate statistical significance.
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